U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   Form 10-QSB

             QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

For the quarter ended September 30, 1999

Commission file no. 0-24921

                         Surgical Safety Products, Inc.
                  --------------------------------------------
                 (Name of small business issuer in its charter)

            New York                                       65-0565144
  -------------------------------                     -------------------
  (State or other jurisdiction of                     (I.R.S. Employer
  incorporation or organization)                      Identification No.)

       2018 Oak Terrace
        Sarasota, Florida                                34231
-------------------------------------                  ----------
(Address of principal executive offices)               (Zip Code)

Issuer's telephone number (941) 927-7874

Securities registered under Section 12(b) of the Exchange Act:


                                             Name of each exchange on
    Title of each class                        which registered

           None
-----------------------------                ------------------------

Securities registered under Section 12(g) of the Exchange Act:

                          Common Stock, $.001 par value
                       -----------------------------------
                                (Title of class)

Copies of Communications Sent to:
                                   Mercedes Travis, Esq.
                                   Mintmire & Associates
                                   265 Sunrise Avenue, Suite 204
                                   Palm Beach, FL 33480
                                   Tel: (561) 832-5696
                                   Fax: (561) 659-5371


<PAGE>






     Indicate by Check  whether the issuer (1) filed all reports  required to be
filed by Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or
for such shorter  period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

                  Yes      X        No
                           ---            ---

         As of September 30, 1999,  there are 11,811,373  shares of voting stock
of the registrant issued and outstanding.




<PAGE>



PART I

Item 1.           Financial Statements


Condensed Balance Sheets as of September 30, 1999 and December 31, 1998    F-2

Condensed Statements of Operations for the Three and Nine Months Ended
September 30, 1999 and 1998                                                F-3

Statements of Cash Flows for the Nine Months Ended
September 30, 1999 and 1998                                                F-4

Notes to the Condensed Financial Statements                                F-6

























<PAGE>



<TABLE>
<CAPTION>

                                           SURGICAL SAFETY PRODUCTS, INC.
                                              CONDENSED BALANCE SHEETS
                                                                  (Unaudited)
                                              September             December
                                                  30                    31,
                                                 1999                  1998
                                            --------------       ---------------
<S>                                         <C>                  <C>
                  Assets
Current Assets
  Cash                                      $       12,970       $       41,191
  Accounts receivable                               16,500                1,941
  Deposits                                             750               58,700
  Inventory                                          5,901                6,555
                                            --------------       ---------------
    Total current assets                            36,121              108,387
                                            --------------       ---------------

Property and equipment, net                        201,151              112,772
                                            --------------       ---------------

Other Assets
  Intangible assets, net                            44,139               49,232
  Software development costs, net                  131,444               92,873
  Other assets                                      10,250               10,250
                                            --------------       ---------------
    Total other assets                             185,833              152,355
                                            --------------       ---------------
Total Assets                                $      423,105       $      373,514
                                            ==============       ===============

Liabilities and Stockholders' Equity

Current Liabilities
  Line of credit                            $       50,000       $
  Notes payable - related parties                   52,500
  Deferred revenue                                   6,874
  Accounts payable and accrued expenses             72,005               55,331
    Total current liabilities                      181,379               55,331

Stockholders' Equity
  Common stock, $.001 par value,
    20,000,000 shares authorized;
11,798,373 and 10,746,973 shares issued
    and outstanding in 1999 and 1998                11,799               10,787
  Additional paid-in capital                     2,422,420            1,998,242
  Accumulated deficit                           (2,192,493)          (1,690,846)
    Total stockholders' equity                     241,726              318,183

Total Liabilities and Stockholders' Equity  $      423,105       $      373,514
</TABLE>


                 The accompanying notes are an integral part of
                          these financial statements.
                                       F-2


<PAGE>




<TABLE>
<CAPTION>
                         SURGICAL SAFETY PRODUCTS, INC.
                       CONDENSED STATEMENTS OF OPERATIONS

                                                9 Months ended          Three Months Ended
                                                 September 30,              September 30,
                                               1999       1998           1999           1998
<S>                                      <C>           <C>            <C>           <C>
Revenue
   Net sales                             $       720   $      797     $      240    $      355
   Leasing and other fees                    162,577       38,007        111,264
   Other                                       1,924        6,910            984         6,059
income
    Total revenue                            165,221       45,714        112,488         6,414

Costs and expenses
  Cost of medical products sold               14,271        1,966          5,866           687
  Operating expenses                         602,555      497,649        207,321       174,867
  Research and development expenses           40,287                                    20,202
  Interest expense                             9,755       13,639          2,315           186
    Total costs                              666,868      513,254        235,704       175,740

Net loss before income taxes                (501,647)    (467,540)      (123,216)     (169,326)

Provision for income taxes

Net loss                                 $  (501,647)   $(467,540)     $(123,216)    $(169,326)

Net loss per share                       $    (0.045)   $  (0.045)     $  (0.010)    $  (0.016)
</TABLE>

                 The accompanying notes are an integral part of
                          these financial statements.

                                       F-3




<PAGE>



<TABLE>
<CAPTION>

                         SURGICAL SAFETY PRODUCTS, INC.
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

                                                                    Nine months ended
                                                                      September 30,
                                                                  1999            1998
<S>                                                       <C>              <C>
Cash Flows From Operating Activities
  Net loss                                                $   (501,647)    $(467,540)
  Adjustments to reconcile net loss to cash
    used in operating activities
      Depreciation and amortization                             86,680        24,562
      Common stock issued for services and
           employee compensation                                41,303       141,875
      Stock option compensation expense                        (91,113)
      Decrease (increase) in operating assets
        Receivables                                            (14,559)      248,487
      Inventory                                                    654        (6,885)
  Increase (decrease) in operating liabilities
         Deferred revenue                                        6,874
    Accounts payable and accrued expenses                       16,674       (45,161)
          Total adjustments                                     46,513       362,878
            Net cash used in operating activities             (455,134)     (104,662)

Cash Flows From Investing Activities
  Furniture and equipment purchased                            (93,239)      (61,195)
  Software development additions                               (57,348)      (67,528)
    Net cash used in investing activities                     (150,587)     (128,723)

Cash Flows From Financing Activities
  Proceeds from related party loans                             77,500
  Advances/(repayments) on line of credit,                      50,000      (100,000)
net
  Repayment of stockholder loans                               (25,000)     (233,720)
  Proceeds from issuance of common stock                       475,000       939,000
    Net cash provided by financing activities                  577,500       605,280

Net increase (decrease) in cash                                (28,221)      371,895
Cash at beginning of period                                     41,191             -
Cash at end of period                                     $     12,970     $ 371,895

Supplemental Cash Flow Information:
  Cash paid for interest                                  $      5,474     $  31,678
</TABLE>


                    The accompanying notes are an integral part
                         of these financial statements.
                                       F-4



<PAGE>





For purposes of the statement of cash flows,  management  considers all deposits
and financial  instruments with original maturities of less than three months to
be cash and cash equivalents.

Material  non-cash  transactions  not  reflected in the  statement of cash flows
include:

For the Nine Months Ended September 30, 1999
  The Company  received  fixed  assets in the amount of $58,700 for which it had
    recorded deposits of such amount at December 31, 1998.

For the Nine Months Ended September 30, 1998
  TheCompany  issued  common  stock  for  prepaid  legal  and  public  relations
     services in the amount of $47,500 as of September 30, 1998


                   The accompanying notes are an integral part
                         of these financial statements.
                                       F-5



<PAGE>




                   Notes to the Condensed Financial Statements
Note 1 - Account Policies

Basis of Presentation
The condensed financial  statements of Surgical Safety Products,  Inc. (Company)
have been prepared  without audit,  pursuant to the rules and regulations of the
Securities and Exchange Commission. Certain information and footnote disclosures
normally included in financial  statements prepared in accordance with generally
accepted  accounting  principles have been condensed or omitted pursuant to such
rules and regulations. These consolidated financial statements should be read in
conjunction  with the  financial  statement  and notes  thereto  included in the
Company's Annual Report on Form 10-KSB for the year ended December 31, 1998.

The results of operations for the nine month period ended September 30, 1999 are
not necessarily indicative of the results to be expected for any other period or
for the full year.

In the opinion of Company's  management  the  accompanying  unaudited  financial
statements  contain  all  adjustments,  consisting  of only  normally  recurring
adjustments,  necessary to present fairly the financial position as of September
30, 1999, the results of operations and cash flows for the three and nine months
ended September 30, 1999 and September 30, 1998.

Net Loss Per Share
Net loss per share has been computed in accordance  with  Statement of Financial
Accounting  Standards (FASB) no. 128, "Earnings Per Share," by dividing net loss
by the weighted average number of shares outstanding  during the period.  Common
stock  equivalents  have not been include in the computation of weighted average
number of shares outstanding since the effect would have been anti-dilutive.

Reclassifications
Certain   reclassifications  have  been  made  in  the  prior  year's  financial
statements to conform to the current period presentations.

Note 2 - Stock Compensation Expense
During fiscal year 1998, the Company issued stock options with an exercise price
that was below  market to certain of its  employees.  Accordingly,  the  Company
recorded  $91,113 of  compensation  expense related to the issuance for the year
ended December 31, 1998.

In the first  quarter of 1999,  the Company  canceled  these  stock  options and
issued  options with an exercise  price above that of market.  Accordingly,  the
Company  decreased its payroll expenses by $91,113 for the cancellation of these
options for the nine months ended  September 30, 1999.  In addition,  during the
nine months ended  September 30, 1999, the Company issued common stock valued at
$39,053 to certain of its employees and $7,500 to certain consultants in lieu of
cash  compensation  for services.  The common stock was valued based on the fair
market value for the shares on the dates the compensation would have been paid

                                       F-6


<PAGE>



Item 2. Management's Discussion and Analysis of Results of Operations.

General

         On July 30, 1999,  the Company  entered into a long term agreement with
US  Surgical  which is a private  partner  network  agreement  (the  "Long  Term
Agreement"). Under the Long Term Agreement, Surgical agreed to sell four hundred
(400)  licenses for the use of one or more OASiS systems and US Surgical  agreed
to nominated four hundred (400) hospitals for such licenses. Each license is for
a term of three (3) years  commencing with  "substantial  installation"  of such
unit. "Substantial installation" is defined as delivery of the OASiS unit to the
hospital and connection to the Internet.

         Under the terms of the Long Term  Agreement,  US Surgical must purchase
two  hundred  (200)  licenses  within  the first  year,  and  subject to certain
obligations  on the part of Surgical  to license  units to third  parties,  must
purchase an additional two hundred (200) licenses by the end of the second year.
Hospital  s with units  installed  under the Short Term  Agreement  are  counted
toward the minimum number of hospitals required.  On August 10, 1999 US Surgical
paid Surgical  $100,000.00 as a  non-refundable  down payment for such licenses.
The first 200 licenses are an additional $1,500 each and subsequent licenses are
$1,000 each.

         The Long Term Agreement further provides that neither Surgical, nor any
third  party  other  than US  Surgical,  may  place  OASiS  units  in any of the
"protected  departments"  of the  hospitals,  unless  it is  installed  prior to
receipt of a purchase  order from US  Surgical  or unless US  Surgical  does not
exercise  its  right  of first  refusal  after  notice  from  Surgical  for such
hospital.  The Long Term Agreement defines "protected  departments" as Operating
Room,  Labor  and  Delivery,  Emergency  Room,  Ambulatory/Same  Day  Surgery  /
Outpatient,  Nuclear Medicine,  Intensive Care, Orthopedic / Ortho Casting Room,
and Dialysis. US Surgical is required to have each hospital bear the entire risk
of loss  and  damage  to any  OASiS  system  except  if such  is  caused  by the
negligence or willful misconduct of Surgical. US Surgical must maintain casualty
insurance  in amounts  and with  companies  acceptable  to Surgical on the OASiS
units and its related amenities with Surgical as the loss payee. US Surgical may
elect to have the OASiS systems  installed in hospitals it nominates  co-branded
with its name.  Surgical  has the  discretion  to select  the  content,  related
services and in- service  products for the OASiS  systems  installed  under this
agreement; however, during the term of the agreement, US Surgical is required to
pay for and maintain a minimum of one hundred  forty (140)  product  in-services
modules  in an  average of at least 80% of all OASiS  systems  installed  in the
United  States  whether or not covered by this  agreement and 100% on those that
are covered by the agreement.  US Surgical's  product-based  modules produced by
Surgical  become the  property  of US  Surgical.  Surgical  retains the right to
display such modules on other OASiS units. All other modules remain the property
of Surgical.  Surgical receives a fee for production of the modules. If Surgical
installs additional OASiS units in a designated hospital, US Surgical receives a
10% commission.  Surgical  receives a monthly  maintenance fee for each unit, of
$149,  unless  paid a year in advance in which case it may be  discounted  up to
10%.

         In  July  1999,  the  Company  executed  a  Consulting  and  Assistance
Agreement with Triton Capital, Inc., a Florida corporation ("Triton"). Under the
terms of this agreement,  Triton has been engaged to identify sources of capital
or  potential  business  relationships  and to assist the Company in (i) raising



<PAGE>



equity or debt  financing in the amount of $6,000,000  (ii)  arranging for trade
financing for production, sale, lease, rental or other disposal of the Company's
products;  and (iii) arranging for the sale,  merger,  or  consolidation  of the
Company or for joint  ventures or  strategic  alliances  with other  appropriate
business. This agreement is non-exclusive.  In the event Investment Financing is
secured,  the Company  was to pay  compensation  equal to 8% for any  investment
financing to the person or entity placing such investment;  provided such person
or entity is qualified to receive such compensation in the state of residence of
the investor and will issue warrants to purchase  restricted Common Stock in the
Company in an amount equal to 100,000 for every $1 million  funded,  exercisable
for a period of five (5) years at a price  equal to the closing bid price of the
Company's  shares on the date of such  funding  and which  warrants  are to have
piggy-back registration rights and cashless exercise provisions.  The Company is
free to reject any offered financing or arrangements; however, in the event that
the Company enters any arrangement within 180 days of its written rejection,  on
terms less  favorable  to the  Company,  Triton is to receive a flat fee. In the
event the  Company  "shops"  any  offer of  financing  presented  to it to other
potential  sources and  accepts  such other  financing,  Triton is entitled to a
success fee. Triton is to be reimbursed pre-approved disbursements and expenses.
The  agreement  provides for  confidentiality  and  cross-indemnification  . The
agreement is subject to  cancellation by either party with five (5) days written
notice.  Any  disputes  under the  agreement  are  required to be  submitted  to
arbitration,  with  costs  payable by the losing  party.  No funding  under this
agreement has been received as of the date hereof.

Discussion and Analysis

         The  Company  was  founded  in 1992 to combat the  potential  spread of
bloodborne pathogenic infections such as HIV and hepatitis. It has broadened its
mission to  research,  develop,  manufacturing,  marketing  and selling  medical
products and services to the healthcare community.

         The  Company  was in the  development  stage  until  1993 when it began
commercial  shipments of  SutureMate(R),  its first  product.  From inception in
June,  1992  through  December  31,  1998,  the  Company  generated  revenues of
approximately  $1,100,000  from a limited number of customers.  Since  inception
through  December  31,  1998,  the Company has  generated  cumulative  losses of
approximately  $1,690,000.  Although the Company has  experienced  a significant
percentage  growth in revenues from fiscal 1992 to fiscal 1998, the Company does
not believe  prior  growth rates are  indicative  of future  operating  results,
especially  in  light  of  the  contract  with  US  Surgical  to  assist  in the
introduction  of OASiS.  Due to the  Company's  operating  history  and  limited
resources,  among other factors, there can be no assurance that profitability or
significant  revenues on a quarterly  or annual  basis will occur in the future.
Moreover,  the Company expects to continue to incur operating  losses through at
least the first half of 2000, and there can be no assurance that losses will not
continue after such date. The Company had  commitments  for  installations  in a
total of 12 hospitals on or before June 30,  1999,  ten of which  related to the
agreement  with  US  Surgical  and  two  are a  result  of the  Company's  sales
department.  As of the date hereof the Company has  completed  installations  of
fourteen  (14)  units in seven  (7)  hospitals,  five (5) of which are under the
original  agreement with US Surgical.  Installation of the remaining units under
the US Surgical initial agreement have been merged into the Long Term Agreement.

         With the  implementation  of its agreement  with US Surgical and in the
event of the reactivation of its various distribution agreements and/or with the
establishment of one or more strategic alliances in addition to US Surgical, the
Company  expects  to  experience  a  period  of  growth,  which  requires  it to



<PAGE>



significantly  increase the scale of its operations.  This increase will include
the  hiring of  additional  personnel  in the areas of (i)  customer  service to
provide technical support for the hospitals where  installations are located and
(ii) technical  staff to make changes  requested by those  hospitals.  This will
result in  significantly  higher operating  expenses.  The increase in operating
expenses is expected to be partially funded by an increase in revenues. However,
the  Company's  net loss may  continue to increase.  Expansion of the  Company's
operations may cause a significant strain on the Company's management, financial
and other  resources.  The  Company's  ability to manage recent and any possible
future growth,  should it occur, will depend upon a significant expansion of its
sales and  marketing,  research and  development,  accounting and other internal
management  systems  and the  implementation  and  subsequent  improvement  of a
variety of systems,  procedures  and  controls.  There can be no assurance  that
significant  problems in these areas will not occur. Any failure to expand these
areas and  implement  and improve such  systems,  procedures  and controls in an
efficient  manner at a pace consistent with the Company's  business could have a
material  adverse  effect on the  Company's  business,  financial  condition and
results  of  operations.  As  a  result  of  such  expected  expansion  and  the
anticipated  increase in its operating  expenses,  as well as the  difficulty in
forecasting  revenue  levels,  the Company  expects to  continue  to  experience
significant fluctuations in its revenues, costs and gross margins, and therefore
its results of operations.

         The Company's plan of operations for the next twelve months is to focus
on building  revenue from the  installation of the OASiS system in the hospitals
designated by US Surgical and to install  additional  OASiS systems in hospitals
not  under  the US  Surgical  agreement  but with  whom the  Company  has  begun
negotiations and in some cases reached a commitment.  Additionally,  the Company
intends to install the  inservice  modules  from US Surgical  and other  medical
product  manufacturers  at both the US  Surgical  and the other  hospitals.  The
Company also is aggressively  seeking strategic alliances with targeted industry
partners such as  manufacturers of devices,  manufacturers  of  pharmaceuticals,
professional  organizations  such as nursing  associations  and  hospital  group
purchasing organizations and integrated health networks.

         The Company  estimates that revenues will be sufficient to fund ongoing
operations at the current level when the number of OASiS  installations  reaches
approximately  100 to 125 and the total  number  of  inservice  modules  reaches
approximately  150.  The  Company  has  purchased  20  OASiS  units  from  Kiosk
Information  Systems,  Inc.,  of which eleven (11) were  installed  under the US
Surgical  agreements and at St.  Francis  Hospital.  The Company  already has 32
inservice  modules under the US Surgical  agreement  and is in  discussion  with
various  manufacturers  interested  in using OASiS to inservice  more than 50 of
their  products.  The Company  believes  that each of the initial  installations
should have a position as to long term  acceptance  within  three (3) to six (6)
months and that this initial time is the test period to determine  the potential
for market  acceptance at that  hospital.  In the case of US Surgical  hospitals
under the initial agreement, this period was nine (9) months by contract. At the
end of such test  period,  the  Company  believes  it will be in a  position  to
execute  three (3) year  leases and  finance  such  leases  through a  leveraged
leasing arrangement with Rockford or a similar funding source.

         In the short term, to fund operations through the fourth quarter, 1999,
the Company will be required to seek additional  funds from strategic  alliances
with potential clients, its shareholders,  from additional third party financing
or seek third  party debt or equity  financing  other than those  planned by the
current anticipated private placement.  Currently, the Company has exhausted its
existing  lines of  credit.  Therefore,  the  Company  has  begun to scale  back
operations.  The  Company is exploring a program to substitute stock for cash in


<PAGE>



in its  compensation  program.  In addition,  immediate focus is being placed on
other  methods to reduce its  breakeven  point,  such as staffing  cuts,  or the
licensing  or sale of some of the  Company's  assets or  product  lines to third
parties.  Provided that additional funding or its scale back is successful,  the
Company  believes that it can meet its capital needs through year end. There can
be no assurance that the Company will be successful in these efforts.

         In  2000,  the  Company  will  require  between  $8 and $9  million  in
additional capital in the form of debt or equity to fund the continued expansion
of the  OASiS  system  and its  development  to  meet  increased  demand  and to
implement its plans for increased marketing of its medical device products.  The
Company  has  met  with  several  venture  capital  firms,  investment  bankers,
factoring companies and traditional lending sources, each of whom have expressed
early  interest  and many of whom are  awaiting  the  conclusion  of the testing
period.  The Company has accepted no definite  offer,  with the exception of the
short term funding being sought through  Triton.  There can be no assurance that
such long-term  financing will be available to the Company or that it will be on
terms that the Company may seek.

Results of Operations for the Three and Nine Months Ended September 30, 1999 and
1998

Overview

         From its inception, the Company has incurred losses from operations. As
of  September  30,  1999,  the  Company  had  cumulative  net  losses   totaling
approximately $2,192,493.  Through fiscal 1998, the Company focused primarily on
the design and  development  of its  propriety  products,  as well as  providing
consulting  services.  During  fiscal  1999,  management  shifted  its  focus to
aggressively marketing its proprietary products.

Financial Position

         Working capital as of September 30, 1999 was a deficit of $145,258,  as
compared to working  capital of $53,056 at December 31, 1998.  This  decrease is
primarily  due to  additional  borrowings  on the  Company's  line of credit and
increases in Notes payable-related parties, the transfer of deposits to property
and equipment and the reduction in cash.

Revenues

         For the three months ended September 30, 1999 and 1998, the Company had
total revenues of $112,488 and $6,414, respectively.  For the three months ended
September 30, 1999,  revenues were comprised  primarily of the initial  payments
received from US Surgical  associated with the Long Term Agreement and for Oasis
unit rentals.  For the nine months ended September 30, 1999, total revenues were
$165,221  compared  to $45,741 in the same  period  last year.  The  increase of
$119,507 or 261% is due to revenue from the 1999 launch of Oasis. In 1998, Oasis
was still under development.

Selling, General, and Administrative Expenses

         For the nine  months  ended  September  30,  1999,  operating  expenses
increased by $104,906 or 21% from  $497,649 for the nine months ended  September
30, 1998. This increase is primarily related to marketing  support  expenditures
to sustain  the launch of the Company's Oasis system.  In  accordance  with  the


<PAGE>



Company's marketing plan for fiscal 1999,  expenses related to promotion,  trade
shows, and conventions  were increased to enhance the industry  awareness of the
company's products and services.

         In the past,  the Company has focused on the design and  development of
proprietary  products.  For fiscal 1999,  the Company has launched an aggressive
marketing  plan that is designed to increase  worldwide  sales of its  products.
Surgical believes that the increased operating expenses incurred during the nine
months ended September 30, 1999 will position the Company to generate  increased
revenue in the 2000 fiscal year.

Liquidity and Capital Resources

         The Company's  operations have been funded  primarily from the $475,000
proceeds of the private placement  completed in the second quarter 1999 and from
cash flow of $107,500 from shareholder  loans and advances on the line of credit
during the nine months ended  September  30,  1999.  This allowed the Company to
purchase capital assets, enhance its OASiS software and fund current operations.
At September 30, 1999, the Company has a $12,970 cash position.

         The Company has a line of credit in the amount of $100,000 that expires
in May 2017 and is guaranteed by Dr. Swor and his wife.  The line of credit also
has been used to fund operations on a short-term basis and $100,000 is currently
outstanding.

         Net cash used for  investing  for the nine months ended  September  30,
1999 was approximately  $150,587,  representing  primarily OASiS units purchased
and costs related to the new version of OASiS which have been capitalized.

         In the short term, to fund operations through the fourth quarter, 1999,
the Company will be required to seek additional  funds from strategic  alliances
with potential clients, its shareholders,  from additional third party financing
or seek third  party debt or equity  financing  other than those  planned by the
current anticipated private placement.  Currently, the Company has exhausted its
existing  lines of  credit.  Therefore,  the  company  has  begun to scale  back
operations.  The company is exploring  programs to substitute  stock for cash in
its compensation programs. In addition, immediate focus is being placed on other
methods to reduce its breakeven point, such as staffing cuts or the licensing or
sale of some of the Company's assets or product lines to third parties. Provided
that additional funding is secured and its scale back is successful, the Company
believes that it can meet its capital  needs  through year end.  There can be no
assurance that the Company will be successful in these efforts.

Impact of the Year 2000 Issue

         The Year 2000 Issue is the result of potential  problems  with computer
systems or any equipment  with computer  chips that use dates where the date has
been stored as just two digits (e.g. 98 for 1998). On January 1, 2000, any clock
or date recording  mechanism  including date sensitive  software which uses only
two digits to represent  the year,  may  recognize the date using 00 as the year
1900  rather  than the year  2000.  This  could  result in a system  failure  or
miscalculations causing disruption of operations,  including among other things,
a temporary  inability  to process  transactions,  send  invoices,  or engage in
similar activities.



<PAGE>



         Management  has  reviewed  its current  internal  systems and is in the
process  of  upgrading  its  accounting  system to be Year 2000  compliant.  The
Company purchased new hardware in 1998 that is Year 2000 compliant. Its internal
systems  are Year 200  compliant  and the  Company  expects  the testing of such
systems to be  completed  in the fourth  quarter  of 1999.  Management  does not
anticipate any significant  additional  costs that would relate to upgrading its
systems to support the Year 2000.

         Further,  management  does not  believe  the Year 2000 will  impact the
operation  of the OASiS  system since the software for this system does not rely
on legacy  applications or subsystems.  OASiS is designed to handle dates in the
form of a two digit month and day and a four digit year,  thus avoiding the Year
2000 problem

         The Company  believes that it has  disclosed  all required  information
relative to Year 2000 issues relating to its business and  operations.  However,
there can be no  assurance  that the  systems  of other  companies  on which the
Company's  systems rely also will be  converted  in a timely  manner or that any
such failure to convert by another  company would not have an adverse  affect on
the Company's business, operations or financial condition.

Forward-Looking Statements

         This Form  10-QSB  includes  "forward-looking  statements"  within  the
meaning of Section 27A of the  Securities  Act of 1933, as amended,  and Section
21E of the Securities  Exchange Act of 1934, as amended.  All statements,  other
than  statements of historical  facts,  included or incorporated by reference in
this Form 10-QSB which  address  activities,  events or  developments  which the
Company expects or anticipates  will or may occur in the future,  including such
things as future capital expenditures (including the amount and nature thereof),
demand for the  Company's  products and  services,  expansion  and growth of the
Company's  business and operations,  and other such matters are  forward-looking
statements.  These statements are based on certain assumptions and analyses made
by the  Company in light of its  experience  and its  perception  of  historical
trends,  current  conditions and expected  future  developments as well as other
factors it believes  are  appropriate  in the  circumstances.  However,  whether
actual results or developments will conform with the Company's  expectations and
predictions is subject to a number of risks and uncertainties,  general economic
market and business  conditions;  the business  opportunities  (or lack thereof)
that  may be  presented  to and  pursued  by the  Company;  changes  in  laws or
regulation;  and other  factors,  most of which are  beyond  the  control of the
Company.  Consequently,  all of the forward-looking statements made in this Form
10-QSB  are  qualified  by  these  cautionary  statements  and  there  can be no
assurance  that the actual  results or  developments  anticipated by the Company
will be realized  or, even if  substantially  realized,  that they will have the
expected consequence to or effects on the Company or its business or operations.
The  Company   assumes  no  obligations  to  update  any  such   forward-looking
statements.

PART II

Item 1.  Legal Proceedings.

         The Company knows of no legal  proceedings to which it is a party or to
which any of its  property is the  subject,  which are  pending,  threatened  or
contemplated or any unsatisfied judgments against the Company.


<PAGE>




Item 2. Changes in Securities and Use of Proceeds

         None

Item 3. Defaults in Senior Securities

         None

Item 4. Submission of Matters to a Vote of Security Holders.

         No matter was submitted  during the quarter ending  September 30, 1999,
covered by this  report to a vote of the  Company's  shareholders,  through  the
solicitation of proxies or otherwise.

Item 5. Other Information

         None

Item 6. Exhibits and Reports on Form 8-K

     (a) The exhibits  required to be filed  herewith by Item 601 of  Regulation
S-B, as described in the following index of exhibits, are incorporated herein by
reference, as follows:

Exhibit No.             Description
-------------------------------------------------------------------------------

3.(I).1   Articles of Incorporation of Surgical Safety Products,
          Inc., a Florida corporation filed May 15, 1992

3.(I).2   Articles of Amendment filed December 9, 1992

3.(I).3   Articles of Amendment filed July 19, 1994

3.(I).4   Articles of Amendment filed October 11, 1994

3.(I).5   Articles of Incorporation of Sheffeld Acres, Inc.,
          a New York Corporation filed May 7, 1993

3.(I).6   Articles of Merger filed in the State of Florida October 12, 1994

3.(I).7   Certificate of Merger filed in the State of New York February 8, 1995

3.(I).8   Certificate to Do Business in the State of Florida filed April 11,1995

3.(I).9   Certificate of Amendment filed May 1, 1998



<PAGE>



3.(II).   Bylaws of Sheffeld Acres, Inc., now known as
          Surgical Safety Products, Inc.

3.(II).   Amended Bylaws of Surgical Safety Products, Inc.

10.1      Acquisition of Endex Systems, Inc. d/b/a/ InterActive PIE
          dated December 8, 1997

10.2      Prepaid Capital Lease Agreement with Community Health Corporation
          relative to Sarasota Medical Hospital OASiS Installation
          dated January 30, 1998

10.3      Letter of Intent with United States Surgical Corporation
          dated February 12, 1998

10.4      Form of Rockford Industries, Inc. Rental Agreement and
          Equipment Schedule to Master Lease Agreement

10.5      Ad-Vantagenet Letter of Intent dated June 19, 1998

10.6      Distribution Agreement with Morrison International Inc.
          dated September 30, 1996

10.7      Distribution Agreement with Hospital News dated August 1, 1997

10.8      Clinical Products Testing Agreement with Sarasota Memorial Hospital
          dated January 30, 1998

10.9      Real Estate Lease for Executive Offices effective June 1, 1998

10.10     Employment Agreement with Donald K. Lawrence dated April 1, 1997

10.11     Employment Agreement with G. Michael Swor dated June 15, 1998

10.12     Employment Agreement with Frank M. Clark dated June 15, 1998

10.13     Agreement for Consulting Services with Stockstowatch.com Inc.
          dated March 30,  1988

10.14     Form of Employee Option Agreement dated July 1994

10.15     Form of Employee Option Agreement dated 1998

10.16     Form of Consultants Option Agreement dated July 1994

10.17     Form of Consultants Option Agreement dated 1998

10.18     Confidential Private Offering Memorandum dated May 30, 1995

10.19     Supplement to Private Offering Memorandum dated October 30, 1995

10.20     Stock Option Agreement with Bay Breeze Enterprises LLC
          dated April 9, 1998


<PAGE>




10.21     Revolving Loan Agreement, Revolving Note, Security Agreement
          with SouthTrust Bank dated May 2, 1997

10.22     Agreement between the Company and T. T. Communications, Inc.
          dated October 15, 1998

10.23     Agreement between the Company and U.S. Surgical Corporation
          dated October 28, 1998.

10.24     Collaborative Agreement between the Company and Dr. William B. Saye
          dated November 16, 1998.

10.25     Kiosk Information System, Inc. Purchase Order dated November 3, 1998

10.26     Surgical Safety Products 1999 Stock Option Plan adopted January 1999

10.27     Form of the Employee Option Agreement under the Surgical Safety
          Products 1999 Stock Option Plan dated January 1999

10.28     Form of the Director, Consultant and Advisor Option Agreement under
          the Surgical Safety Products 1999 Stock Option Plan dated January 1999

10.29     Verio, Inc. Access Service Agreement dated February 16, 1999.

10.30     Form of Investor  Subscription  Documents and Agreements
          relative  to the April 1999 Self  Directed  Private  Placement
          Offering under Rule 506 of Regulation D.

10.31     Form of the  Warrant  issued  pursuant to the April 1999
          Self Directed  Private  Placement  Offering  under Rule 506 of
          Regulation D.

10.32     onsulting Agreement dated April 1999 with Koritz Group, LLC.

10.33     Agreement dated April 1999 with KJS Investment Corporation.

10.34     Agreement dated May 1999 with Ten Peaks Capital Corp.

10.35     Private Partner Network Agreement dated July 30, 1999 with US Surgical

10.36     Staff/Client Leasing Agreement dated October 16, 1999,
          as amended September 15, 1999

10.37 *   Agreement dated July 15, 1999 with Triton Capital Inc.

23.2      Publisher's Consent and Article - Michael W. Bebbington, MD, MHSc and
          Mark J.  Treissman,  MD. The Use of a Surgical Assist Device to Reduce
          Glove  Perforations  in  Postdelivery  Vaginal  Repair:  A  Randomized
          Controlled Trial. American Journal of Obstetrics and Gynecology,  Vol.
          175, No. 1, Part I, October 1996


<PAGE>



23.3      Author's Consent and Abstract - Donna J. Haiduven, BSN, MSN, CIC and
          Maria D. Allo, MD. Evaluation of a One-Handed Surgical Suturing Device
          to   Decrease.   Intraoperative   Needlestick   Injuries   and   Glove
          Perforations:  Phases I & II, Conference on Prevention of Transmission
          of  Bloodborne  Pathogens in Surgery and  Obstetrics  Sponsored by the
          American  College of Surgeons  and the Center for Disease  Control and
          Prevention, February 13-15, 1994, Atlanta, GA.

23.4      Publisher's Consents and Article -Mark S. Davis, MD. Sharps Management
          in Surgery. Infection Control & Sterilization Technology,  Vol. 1, No.
          4, April 1995.

27.1 *    Financial Data Street
----------------

(* Filed  herewith,  all other  exhibits  previously  filed as  exhibits  to the
Company's  Form 10-SB,  Form 10-SB  Amendment No. 1, Form 10SB  Amendment No. 1,
Form 10KSB,  Form 10KSB  Amendment  No. 1, its Form 10QSB for the quarter  ended
March 31, 1999 or its Form 10QSB for the quarter ended June 30, 1999 or its Form
10QSB Amendment No. 1 for the quarter ended June 30, 1999.)

     (b) No Reports on Form 8-K were filed  during the quarter  ended  September
30, 1999.

                                   SIGNATURES

         In accordance  with Section 12 of the Securities  Exchange Act of 1934,
the registrant caused this Registration  Statement to be signed on its behalf by
the undersigned, thereunto duly authorized.

                                Surgical Safety Products, Inc. (Registrant)

Date: November __, 1999
                                By:/s/ Frank M. Clark
                                   ----------------------
                                   Frank M. Clark, President and CEO

                                By:/s/ Donald K. Lawrence
                                   -----------------------
                                   Donald K. Lawrence
                                   Vice President and Secretary

                                By:/s/ G. Michael Swor
                                   -----------------------
                                   G. Michael Swor
                                   Treasurer

                                By:/s/ David Collins
                                   -----------------------
                                   David Collins
                                   Acting Chief Financial Officer
[sign page SSP 10QSB 9.30.99]